Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 23:20:36.
doi: 10.1186/s40824-016-0083-1. eCollection 2016.

Liposomal delivery systems for intestinal lymphatic drug transport

Hyeji Ahn  1 , Ji-Ho Park  1
Affiliations
Review

Liposomal delivery systems for intestinal lymphatic drug transport

Hyeji Ahn et al. Biomater Res. .

Abstract

Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocyte-derived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution to intestinal drug translocation will lead to effective oral delivery with liposomal formulations.

Keywords: Chylomicron; First-pass metabolism; Intestinal lymphatic transport; Lipid; Liposome.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Two pathways (portal vein versus lymph) of oral drug transport to systemic circulation
Fig. 2
Fig. 2
Pathways of lipid absorption and chylomicron synthesis within enterocytes
Fig. 3
Fig. 3
Lipophilic drug transport mechanisms by association with lipoproteins
Fig. 4
Fig. 4
Types of lipidic prodrug: a fatty acids, b glycerides and c phospholipids
Fig. 5
Fig. 5
Liposomes with a hydrophilic drug a encapsulated in the aqueous core and a hydrophobic drug b incorporated into the membrane
See this image and copyright information in PMC

References

    1. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Disc. 2003;2:289–295. doi: 10.1038/nrd1067. - DOI - PubMed
    1. Charman WNA, Stella VJ. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986;34:175–178. doi: 10.1016/0378-5173(86)90027-X. - DOI
    1. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Disc. 2007;6:231–248. doi: 10.1038/nrd2197. - DOI - PubMed
    1. Ali Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8:2733–2744. - PMC - PubMed
    1. Wasan KM, et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Disc. 2008;7:84–99. doi: 10.1038/nrd2353. - DOI - PubMed

LinkOut - more resources